Wall Street Zen upgraded shares of enGene (NASDAQ:ENGN – Free Report) from a strong sell rating to a sell rating in a report issued on Saturday.
ENGN has been the subject of a number of other research reports. Citigroup cut enGene from a “market outperform” rating to a “market perform” rating in a report on Friday, May 8th. Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $7.00 to $4.00 in a research note on Friday, May 8th. Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 target price (down from $25.00) on shares of enGene in a research note on Friday, May 8th. Finally, Morgan Stanley downgraded shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research note on Thursday, June 18th. Four analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $11.05.
Get Our Latest Research Report on enGene
enGene Stock Performance
enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. During the same period in the previous year, the business posted $0.51 EPS. Research analysts forecast that enGene will post -1.84 EPS for the current year.
Institutional Investors Weigh In On enGene
Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its position in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares in the last quarter. Raymond James Financial Inc. lifted its stake in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the period. Cresset Asset Management LLC bought a new position in enGene during the 2nd quarter worth about $36,000. Paloma Partners Management Co bought a new position in enGene during the 2nd quarter worth about $38,000. Finally, Jump Financial LLC purchased a new position in enGene during the 4th quarter valued at about $121,000. 64.16% of the stock is owned by institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More
- Five stocks we like better than enGene
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
